The Section of Cellular Therapy

Welcome to the Department of Cellular Therapy which is home to one of Europe’s biggest and most modern GMP facilities for cellular products.

  Dag Josefsen, MD PhD, Head of Department

(Group leaders: E.M. Inderberg and S. Wälchli) has the capacity to undertake complete pre-clinical studies for immunotherapeutic molecules such as vaccines and adoptive T cell transfer (TCR, CAR). It possesses the competence to deliver molecular biology products isolated from patient material (TCR), to perform cellular assays and in vivo animal studies. Finally, innovative tools are also developed in collaboration with academy and private companies.

The Immunomonitoring Lab (Head: E.M. Inderberg) is a heritage from the former research group of Prof. G. Gaudernack and was included in the Department of Cellular Therapy in 2012. It participated to both academic and industrial trials, more information can be found here

Our labs are located at the Oslo Cancer Cluster Incubator OCCI

ACT-centre aims at facilitating the development of novel advanced therapy medicinal products (ATMP) and make novel therapies available to Norwegian patients. More information can be found here


Publication: rechallenge protocol


It's not always easy to recapitulate in vivo activity in plastics. Re-challenge is one of these methods that might contribute to a better understanding of CAR Tc biology, while avoiding the use of animals. This is one of our protocols, there are many more (we hope we cited most of them) and there is still a long road until an artificial environment will be able to help us to predict how T cell will behave in clinical settings.

Here is a link to your free pdf (valid for a month or so):,25QIopT0